PPP2R1A mutations portend improved survival after cancer immunotherapy.

doi:10.1038/s41586-025-09203-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PPP2R1A mutations portend improved survival after cancer immunotherapy.

Nature - 1 Aug 2025

Dai Yibo, Knisely Anne, Yano Mitsutake, Dang Minghao, Hinchcliff Emily M, Lee Sanghoon, Welp Annalyn, Chelvanambi Manoj, Lastrapes Matthew, Liu Heng, Yuan Zhe, Wang Chen, Nie Hao, Jean Stephanie, Montaner Luis J, Hou Jiakai, Patel Ami, Patel Shrina, Fellman Bryan, Yuan Ying, Sun Baohua, Pandurengan Renganayaki Krishna, Cuentas Edwin Roger Parra, Celestino Joseph, Liu Yan, Liu Jinsong, Hillman R Tyler, Westin Shannon N, Sood Anil K, Soliman Pamela T, Shafer Aaron, Meyer Larissa A, Gershenson David M, Vining David, Ganeshan Dhakshinamoorthy, Lu Karen, Wargo Jennifer A, Peng Weiyi, Zhang Rugang, Wang Linghua, Jazaeri Amir A

Abstract excerpt

Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes1-5. Here we studied ICB response in a cohort of patients with ovarian clear cell carcinoma-a cancer type that poses considerable clinical challenges and lacks effective therapies6-8. We observed significantly prolonged overall survival and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Interferon-gamma

Share to Neoplasms

Share to Ovarian Neoplasms

Share to Protein Phosphatase 2

Source

Open in PubMed Open full text

Identifiers

PMID: 40604275
DOI: 10.1038/s41586-025-09203-8
PMCID: PMC12350166

Genes

PPP2R1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

PPP2R1A mutations portend improved survival after cancer immunotherapy.PMID 40604275Read ↗

The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.Semantic proximity Read ↗

PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signalingSemantic proximity Read ↗

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.Semantic proximity Read ↗

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.Semantic proximity Read ↗

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinomaSemantic proximity Read ↗

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Semantic proximity Read ↗

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugsSemantic proximity Read ↗

PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.Semantic proximity Read ↗

Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts.Semantic proximity Read ↗

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancerSemantic proximity Read ↗

New therapies for clear cell ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.